Mikael Dolsten, a renowned pharmaceutical expert, has joined Immunai as a strategic advisor, bringing with him over 25 years of experience in leadership roles at major pharmaceutical companies, including Pfizer, Wyeth, Boehringer Ingelheim, and AstraZeneca. During his 15-year tenure at Pfizer, he led the development of 35 new drugs and vaccines, including the first COVID-19 vaccine, and oversaw research across various therapeutic areas. As a result, he contributed to the development of new treatments for diseases such as rheumatoid arthritis, stroke prevention, and cancer.
Dr. Dolsten’s expertise in leading drug development processes will be crucial in helping Immunai achieve its goal of integrating artificial intelligence (AI) into immunology and oncology. He believes that AI can significantly accelerate drug development by analyzing immune system activity at the single-cell level and enhance the success rates and efficiency of drug development.
Immunai’s AI model for the immune system is transforming how companies approach drug discovery and development. The company’s unique immune atlas, AMICA, and proprietary IDE engine provide valuable insights into drug mechanisms of action, treatment success rates, and biomarkers for treatment success. These insights can be used to determine drug dosage, identify patients who are most likely to respond to treatment, and predict treatment outcomes.
Dr. Dolsten’s appointment is a significant step in the growth of Immunai, which has already collaborated with AstraZeneca and Teva. The company, which has raised $270 million to date, is expanding its team and actively recruiting for data and AI positions. With Dr. Dolsten’s expertise leading the way, Immunai is poised to revolutionize drug development through its cutting-edge AI-driven approach.